



Jun 11, 2021


# © Objectives (Part 2 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus)

In 1 collection

Stephen.Gitelman 1, Jeffrey A. Bluestone2

<sup>1</sup>Professor of Clinical Pediatrics, Department of Pediatrics University of California, San Francisco Room S-679, Campus Box 0434, 513 Parnassus Avenue, San Francisco, CA 94143;

<sup>2</sup>Professor of Medicine, Pathology, Microbiology & Immunology, University of California, San Francisco, Campus Box 0540, 513 Parnassus Avenue San Francisco, CA 94143



ABSTRACT

This is Part 2 of "Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus"

This clinical study is supported by JDRF. The aim of the collection is to determine whether imatinib will slow the progression of the autoimmune destruction of ß cells and lead to the preservation of C-peptide secretion in T1DM and to assess Diabetes-related objectives and safety of Imatinib in new-onset type 1 diabetes mellitus".

**ATTACHMENTS** 

dngubkeaf.pdf

DOI

dx.doi.org/10.17504/protocols.io.bvcvn2w6

PROTOCOL CITATION

Stephen. Gitelman, Jeffrey A. Bluestone 2021. Objectives (Part 2 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus). **protocols.io** https://dx.doi.org/10.17504/protocols.io.bvcvn2w6

COLLECTIONS (i)

÷

Collection of Protocols and Guidelines for Safety and Efficacy of Imatinib for Preserving Betacell Function in New-onset Type 1 Diabetes Mellitus

KEYWORDS

Safety, Efficacy, Imatinib, Beta-Cell Function, New-Onset Type 1 Diabetes Mellitus

LICENSE

This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

May 28, 2021

LAST MODIFIED

Jun 11, 2021

mprotocols.io

06/11/2021

Citation: Stephen.Gitelman, Jeffrey A. Bluestone (06/11/2021). Objectives (Part 2 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus). <a href="https://dx.doi.org/10.17504/protocols.io.bvcvn2w6">https://dx.doi.org/10.17504/protocols.io.bvcvn2w6</a>

### OWNERSHIP HISTORY

May 28, 2021 Urmilas

Jun 03, 2021 Stephen. Gitelman

PROTOCOL INTEGER ID

50293

PARENT PROTOCOLS

Part of collection

Collection of Protocols and Guidelines for Safety and Efficacy of Imatinib for Preserving Beta-cell Function in Newonset Type 1 Diabetes Mellitus

**GUIDELINES** 

### 2.1 PRIMARY OBJECTIVE:

Determine whether imatinib will slow the progression of the autoimmune destruction of ß cells and lead to the preservation of C-peptide secretion in T1DM.

# 2.2 SECONDARY OBJECTIVES

### **Diabetes-related objectives:**

- 1. Assess whether the drug has prolonged clinical efficacy.
- 2. Assess the effect of imatinib on selected secondary clinical outcomes.

## Safety:

1. Determine the safety of imatinib in participants with T1DM, especially with respect to hepatic, bone marrow, cardiac, and cutaneous toxicity

# Mechanistic studies:

- 1. Characterize how imatinib alters general and diabetes-specific immune responses.
- 2. Gain a better understanding of the mechanism of action for imatinib in the maintenance of  $\beta$ -cell function and determine whether the loss of tolerance associated with this disease is reversed.
- 3. Assess effects of imatinib on insulin sensitivity.